Similar results were obtained when animals were assessed in the tail suspension test, another classical task to evaluate depressivelike behavior in rodents (Supplementary Figure S1a) . AbOinduced immobility in the FST was blocked by anti-depressant (fluoxetine) treatment (Figure 1a ). An important feature of depressive disorder is anhedonic behavior, including decreased interest for pleasurable sensorial experiences. Whereas vehicleinjected mice exhibited an expected preference for sucrose solution over plain water, AbO-injected mice did not exhibit such preference, indicating that AbOs instigate anhedonic behavior ( Figure 1b) .
As memory deficit is the main clinical symptom of AD, we investigated the impact of AbOs on mice memory using the novel object recognition (OR) task. Results showed that 24 h after i.c.v. injection, AbO-treated mice spent equal amounts of time exploring both old (familiar) and new (novel) objects, indicating a deficit in declarative recognition memory, whereas vehicleinjected animals exhibited a significant preference for the novel object ( Figure 1c ). Treatment with fluoxetine prevented the memory deficit induced by AbOs (Figure 1c ). Control measurements showed no changes in spontaneous exploratory or locomotor activities of fluoxetine-, saline-, vehicle-or AbO-injected animals during the training phase of the OR test (Supplementary Figure S1c-e). As the hippocampus is a key anatomical structure for OR memory, we sought to determine whether AbOs injected i.c.v. reached the hippocampus. Indeed, robust AbO immunoreactivity was verified using an anti-oligomer monoclonal antibody (NU4) 6 in hippocampi from AbO-injected mice, but not in hippocampi from control vehicle-injected animals (Supplementary Figure S1b) . Together, these results indicate that AbOs have an acute impact on memory, learning and mood in mice, and that fluoxetine treatment prevented both cognitive impairment and depressive-like behavior induced by AbOs.
The beneficial actions of fluoxetine have been partly ascribed to its anti-inflammatory effect. This led us to ask whether AbOs triggered an inflammatory response in the mouse brain. The brains of mice used in the tests described above were analyzed for levels of pro-inflammatory cytokines after i.c.v. injection of AbOs or vehicle. AbO-injected animals showed significantly elevated brain levels of interleukin-1b and tumor necrosis factor-a compared with vehicle-injected animals (Figure 1d , e). Sections from the hippocampus and cortex of AbO-or vehicle-injected mice were further immunostained for the presence of microglia (anti-Iba-1 antibody) and astrocytes (anti-GFAP antibody). Compared with vehicle-injected animals, AbO-injected mice showed markedly increased immunoreactivities for both Iba-1 and GFAP in the hippocampus and cortex 24 h after injection (Figure 1f The current findings establish that AbOs link memory impairment and depressive-like behavior in mice, providing molecular mechanistic support to clinical evidence connecting AD and depressive disorder. The impact of AbOs on mood, learning and memory, and its prevention by fluoxetine, can likely be attributed to the activation of inflammatory pathways (as shown here) and, possibly, to the deregulation of the serotonergic axis. The latter possibility is in line with the observation that pro-inflammatory cytokines impact serotonin metabolism 7, 8 and that increased serotonin levels are associated with lower brain Ab levels in transgenic mouse models of AD and in humans. 9 Moreover, 5-HT1A and 5-HT2A receptors have been reported to be reduced in post-mortem AD brain, 10 and 5-HT1A receptors have been found to be reduced in vivo in AD. 11 Brain disturbances that place a person at risk for developing depression and AD are still largely unknown. By revealing that AbOs underlie both cognitive and depressive-like symptoms in mice, our results suggest a mechanism by which elevated brain levels of AbOs may be linked to changes in cognition and mood in AD. Four recent studies of the coding regions of the human genome (the 'exome'), suggest that new (de novo) mutations in hundreds of genes may contribute to the risk of autism spectrum disorder (ASD). [1] [2] [3] [4] While the experimental strategy in the different efforts is almost identical, the four studies were published independently, and no integrative analysis has yet been reported. Notably, limited conclusions regarding the specific systems of genes disrupted by de novo mutations can be drawn based on each study alone. This stems from the relatively small fraction of mutations identified in each study in which there is a clear functional phenotype at the protein level. Here we show that upon combining the evidence from the different studies and integrating it with gene expression data from the developing human brain, a large group of genes emerges that is involved in regulation of expression during prenatal brain development. This suggests a prominent role in ASD for the genes involved in transcription regulation during brain development, specifically chromatin regulators.
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We analyzed the complete collection of de novo singlenucleotide variations (SNVs) that were identified in 965 probands, sequenced in the four studies. [1] [2] [3] [4] We gathered 121 genes that are most likely to be disrupted, containing de novo SNVs, which are nonsense, frameshift or splice site mutations. To characterize the genes, we first analyzed the enrichment of cellular processes and gene ontology (GO), using the Database for Annotation, Visualization and Integrated Discovery (DAVID). We found a significant enrichment for 'chromatin regulator' (UniProtKB; corrected P ¼ 0.021; Enrichment Score ¼ 2.04). Among the genes in this category, the chromatin remodeling gene CHD8 harbored two mutations in separate individuals (a frameshift and a nonsense mutation).
To test the specificity of these findings to ASD, and to rule out possible confounding factors, we performed the following tests. First, we tested the distribution of disruptive mutations in genes belonging to the keyword 'chromatin regulator' in cases compared with a large control sample (n ¼ 6503), that was also exome sequenced (part of this sample has been recently published 5 ). We found a higher proportion of disruptive mutations in genes belonging to the 'chromatin regulator' category in cases vs controls, supporting the contribution of this category to ASD risk (excluding frameshift mutations, P ¼ 0.0015, odds ratio (OR) ¼ 8.7, 95% confidence interval (95% CI) ¼ 2.3-23.5; including frameshift mutations, P ¼ 2.2 Â 10 À 9 , OR ¼ 13.7, CI ¼ 6.6-25.8). Second, we compared the proportion of disruptive de novo mutations in the unaffected siblings from the Sanders et al. 4 and Iossifov et al. 1 studies. The sibling set contained no disruptive mutation in this category, but given the overall small number of mutations in the unaffected siblings (n ¼ 33), that difference was not significant (P ¼ 0.070, one-sided test). Finally, we examined the proportion of de novo silent mutations in the 'chromatin regulator' category carried by the affected probands themselves. We suggest that those silent mutations in the same individuals could be an ideal control set to test the possible effect of confounding factors. Most (if not all) of the silent mutations are not functional, but should be influenced by the same nonrandom factors that may lead to spurious enrichment of functional categories. Consistent with a direct contribution to ASD, the proportion of disruptive mutations in the 'chromatin regulator' category was significantly higher than the proportion of silent mutations (P ¼ 0.0013, OR ¼ 6.8, 95% CI ¼ 1.8-39.0).
We than asked whether we can cluster the genes on the basis of their expression during the developmental stages of the human brain. For that, we used a published data set of brain gene expression throughout different life stages. 6 Of the 121 genes, 105 had measurements in this data set. To cluster the genes, we used a weighted gene co-expression network analysis (WGCNA) (see Supplementary Methods for details). We identified two modules containing 49 and 26 genes (Supplementary Table S1 ); in addition, we had 30 unassigned genes. We tested the clusters preservation using another expression data set (see Supplementary Methods for details). The gene expression profile of each module is presented in Figure 1a . The largest module is highly expressed during the brain development, with a sharp decrease in expression after birth (hereafter the 'Developmental' module). Functional annotation of this group of genes showed enrichment for 'nucleus', 'transcription regulation', 'chromatin regulator' and 'chromatin modification' (Figure 1b; Supplementary Table S2 ). The second module shows the opposite trend (Figure 1a) , with a sharp increase in expression after birth ('Adult' module), with no significant enrichment for any cellular process. To study the specificity of the enrichment of developmental genes, we used WGCNA to cluster again the disrupted genes, but this time together with genes that contained silent mutations. We then compared the distribution of disruptive vs silent mutations across the modules (Figure 1c) . We found that genes with disruptive mutations were significantly more likely to fall in the 'Developmental' module compared with genes with silent mutations (P ¼ 0.0078, OR ¼ 2.0, 95% CI ¼ 1.2-3.4) .
While it has been proposed that the origins of ASD are at the synapse, our meta-analysis of de novo mutations shows that many of the recently identified mutations are in genes that are involved in transcriptional regulation, specifically chromatin-related proteins, which are active during brain development. Further evidence that lends support to the involvement of chromatin regulation in ASD is that three genes identified in this analysis (ARID1B, SMARCC2 and ADNP) are known to physically interact as a part of ATP-dependent chromatin remodeling complexes, which are essential during neural development. 7 These findings, together with the association of other genes in this category with autism and intellectual disability (for example, MLL3, MBD5), We analyzed the blood transcriptome of 36 drug naive schizophrenia patients and 40 healthy matched controls by nextgeneration sequencing. Among the 22 278 genes analyzed, we found significant differential expression (P-value adjusted o0.05) in 200 genes. These genes are significantly enriched in seven gene ontology biological processes related to protein processing and maturation, innate immune response, acute inflammatory response and response to wounding.
Schizophrenia is a mental disorder with severe consequences that has a lifetime risk of about 1% and heritability estimated at up to 80%. To characterize candidate genes and to obtain functional information regarding the molecular bases of the disease, mRNA from blood was sequenced using a Genome Analyzer IIx from Illumina (San Diego, CA, USA). Peripheral blood was extracted and libraries from total RNA of each individual were constructed using the reagents and the indications of the manufacturer. Single ends of 35 nucleotides were aligned with the human genome (HG18) and reads that passed the quality filtering, aligned uniquely to the genome and had a maximum of two mismatches in the 'seed' (the first 32 nucleotides) were counted. Adjusted P-values (P adj ) of differential expression were obtained with DesEq 1 using the 'fit-only' mode. The expression levels obtained with RNA sequence were validated by quantitative real-time PCR in 10 of the genes with differential expression (Supplementary Information).
We found 200 genes with significant differential expression after adjusting for multiple testing (P adj value o0.05) in the 22 278 human genes analyzed (Supplementary Table 1 and Supplementary Figure 1) . We found a total of 37 genes out of the 200 differential expression genes (19%) in the genome-wide association study (GWAS) Catalog (www.genome.gov/gwastudies) a slight enrichment regarding the 17% fraction of GWASassociated genes. Among these 200 genes, ADAMTS2 has the lowest P adj value (1.3236E À 69) and has been associated with attention-deficit hyperactivity disorder (time to onset) in a GWAS (Supplementary Tables 2 and 3) . 2 Three differentially expressed genes (CSMD1, EHF and RFX2) are associated to schizophrenia in GWAS. CSMD1 associated with schizophrenia among other traits, 3 EHF associated with response to antipsychotic treatment and volumetric brain magnetic resonance imaging in schizophrenia patients, 4, 5 and RFX2, which is not reported but has an intronic SNP with a P-value ¼ 3.5 Â 10 À 6 in a schizophrenia and bipolar disorder GWAS meta-analysis. 6 According to the scientific literature deposited in the GeneRIF repository (National Center for Biotechnology Information), 8 out of the 200 differentially expressed genes have been related to schizophrenia: GRIK3, LPL, S100B, SNCA, SYN2, TUBB2A, SELENBP1, CSMD1; increased levels of S100B have been reported in schizophrenia, which is consistent with our observation of significantly higher expression of the gene in schizophrenia patients. Also, lower copy number of SELENBP1 in schizophrenia patients has been reported, which is consistent with the
